An observational study in NAFLD and NASH (Non-Alcoholic Steatohepatitis), sponsored by Beijing Tsinghua Chang Gung Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Beijing Tsinghua Chang Gung Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 53 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.
Among the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 53rd largest by enrollment of the 54 observational ones that give a count, is one of 11 that started in 2025, is one of 54 observational ones, and was the 143rd registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →42 of the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Liu Yan · Sites in China
Ages 18–65
The Affiliated Hospital of Hangzhou Normal University · Sites in China
Ages 65–100 · Healthy volunteers
Hudson Biotech · Sites in China
Ages 18–75
Eli Lilly and Company · Sites in China, United States, Argentina and 31 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 22 · Phase 3 7 · Phase 4 11
First in 2004; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 152 across 391 observational studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 112 across the 89 interventional studies, 740 across the 54 observational. Of the 63 that completed or were terminated, 6 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 143 have an industry lead sponsor. The 10 most frequent:
Beijing Tsinghua Chang Gung Hospital is the lead sponsor of 113 studies on the registry; 60 are open to participants now.
Beijing Tsinghua Chang Gung Hospital has 3 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
12 of the studies in Non-alcoholic Fatty Liver Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06449833Zhujiang HospitalEffect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD | 2026-11 |
| NCT02863757Humanity and Health Research CentreFollow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease | 2026-12 |
| NCT06569524Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) | 2026-12 |
| NCT07099118Sunshine Lake Pharma Co., Ltd.A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects | 2026-12-30 |
| NCT06717828Fujian Provincial HospitalThe Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational prospective cohort study is to explore the impacts and potential molecular mechanisms of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) on extrahepatic organ injury in adult patients scheduled for partial hepatectomy. The main questions it aims to answer are:
Do patients with NAFLD/NASH suffer more severe extrahepatic organ injury compared with patients without NAFLD/NASH? Are inflammatory mediators (IL-2, IL-6, IL-11) associated with the severity of NAFLD/NASH and extrahepatic organ damage?
Researchers will compare the NAFLD/NASH group (n=18) with the non-NAFLD/NASH group (n=18) to see if NAFLD/NASH aggravates extrahepatic organ injury and correlates with elevated levels of serum and urinary inflammatory mediators .
Participants will:
Study subjects are adult patients with definite preoperative diagnoses scheduled for partial hepatectomy, who are enrolled from the Hepatobiliary-Pancreatic Center, Beijing Tsinghua Changgung Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Not applicable- observational study
Other: Not applicable- observational study
Not applicable- observational study
Differences in laboratory and instrumental examination results related to various extrahepatic organs related to various extrahepatic organs between the two groups
Time frame: at baseline and within 7 days after surgery
Disease stage of prticipants in the NAFLD/NASH group
Time frame: pre-operative
IL-2, IL-6 and IL-11 expression levels for inter-group comparison of inflammatory status
Time frame: pre-operative
Correlations of disease stage with inflammatory mediator levels and extrahepatic organ function
Time frame: 7 days after surgery
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Nov 2025, 8 months.
Of 160 non-industry observational studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 125. This study's 8 months is below that.
Counting every sponsor, half of 171 studies reached it within 49 months; a quarter within 24 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →
Beijing Tsinghua Chang Gung Hospital →